Symptom-Specific Hospital Contacts in 12–18-Year-Olds Vaccinated against COVID-19: A Danish Register-Based Cohort Study

Selina Kikkenborg Berg*, Helle Wallach-Kildemoes, Line Ryberg Rasmussen, Ulrikka Nygaard, Nina Marie Birk, Henning Bundgaard, Annette Kjær Ersbøll, Lau Caspar Thygesen, Susanne Dam Nielsen, Anne Vinggaard Christensen

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

2 Citationer (Scopus)
14 Downloads (Pure)

Abstract

In this register-based real-life cohort study, changes in symptom-specific hospital contacts among 12–18-year-olds following two doses of the BNT162b2 COVID-19 vaccine compared to unvaccinated peers were investigated. Using national register data, vaccinated and unvaccinated adolescents were sex and age-matched each week during the inclusion period from May to September 2021. Symptom-specific hospital contacts covering ICD-10 R diagnoses were assessed before first the vaccine dose and after the second vaccine dose. Taking previous rates of symptom-specific hospital contacts into account, differences between vaccinated and unvaccinated adolescents were found. For some hospital contacts, higher rates were seen among the vaccinated, and for others, higher rates were seen among the unvaccinated. Unspecific cognition symptoms may be important to monitor in vaccinated girls, and likewise for throat and chest pain in vaccinated boys within the first months post-vaccination. In perspective, symptom-specific hospital contacts after vaccination against COVID-19 must be assessed by taking the risk of infection and symptoms following COVID-19 infection into account.
Keywords: COVID-19; children and adolescents; vaccine; symptoms
OriginalsprogEngelsk
Artikelnummer1049
TidsskriftVaccines
Vol/bind11
Udgave nummer6
Antal sider15
ISSN2076-393X
DOI
StatusUdgivet - jun. 2023

Bibliografisk note

Funding Information:
S.D.N. declares a research grant from Novo Nordic Foundation, a travel grant from Gilead, and that she is on the Advisory board for Gilead. G.S.K., M.S.D., and H.B. received lecture fees from Amgen, Sanofi, B.M.S., and M.S.D. None of the other authors have any conflicts to declare.

Funding Information:
This work was supported by the A.P. Møller and Chastine Mc-Kinney Møller Foundation (2021-00661). The study funder was not involved in the study.

Publisher Copyright:
© 2023 by the authors.

Citationsformater